Publications by authors named "J T Caranfa"
Purpose: To assess efficacy and safety of brolucizumab versus aflibercept in patients with diabetic macular edema (DME).
Patients And Methods: We performed a systematic review and meta-analysis with trial sequential analysis (TSA). We searched Embase, Cochrane Central Register of Controlled Trials and PubMed databases from inception to February 16, 2024 for randomized controlled trials (RCTs) comparing brolucizumab with aflibercept in patients with DME and reporting any of the visual, anatomical and safety outcomes of interest.
To determine the efficacy of switching to intravitreal (IVT) faricimab in patients with treatment-resistant neovascular age-related macular degeneration (nAMD) and determine the rates of reversion to original antivascular endothelial growth factor (anti-VEGF) therapy. A retrospective chart review was performed of patients with nAMD and persistent fluid on optical coherence tomography previously treated with anti-VEGF injections who received at least 1 IVT faricimab injection between March 1, 2022, and January 31, 2023. The study comprised 135 eyes of 119 patients.
View Article and Find Full Text PDFTo assess the long-term safety and clinical outcomes of a ganciclovir intravitreal implant in patients with cytomegalovirus (CMV) retinitis. A retrospective study was performed of patients with CMV retinitis treated with a ganciclovir intravitreal implant. The study included 13 patients (16 eyes) previously treated with a ganciclovir intravitreal implant.
View Article and Find Full Text PDFIntroduction: Deferasirox is the only iron chelator available in oral formulation and a rare cause of pigmentary retinopathy. We report the first case of multimodal imaging in an adult with deferasirox retinopathy.
Methods: Case report and literature review, with search terms including deferasirox retinopathy and deferasirox toxicity.